IL33 and neoplasm: Moving forward, the key challenge will be determining whether the same TLS-inducing pathway exists in humans and whether clinical trials can validate the efficacy of an IL-33-based therapy in boosting anti-tumor immunity and improving patient outcomes in PDAC.